Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia. |
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
BH5dbmDfyPdCpm6q
